A Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg×5) and Lamotrigine Compressed Tablet (25mg) in Healthy Chinese Male Subjects.

Trial Profile

A Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg×5) and Lamotrigine Compressed Tablet (25mg) in Healthy Chinese Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2013

At a glance

  • Drugs Lamotrigine (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Most Recent Events

    • 02 Aug 2013 Official title amended as reported by ClinicalTrials.gov.
    • 02 Aug 2013 Planned End Date changed from 1 Aug 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 24 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top